These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 8941467)

  • 1. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
    Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
    Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.
    Colwell JA
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):131-5. PubMed ID: 8554205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM).
    Azad N; Emanuele NV; Abraira C; Henderson WG; Colwell J; Levin SR; Nuttall FQ; Comstock JP; Sawin CT; Silbert C; Rubino FA
    J Diabetes Complications; 1999; 13(5-6):307-13. PubMed ID: 10765007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM).
    Abraira C; Emanuele N; Colwell J; Henderson W; Comstock J; Levin S; Nuttall F; Sawin C
    Diabetes Care; 1992 Nov; 15(11):1560-71. PubMed ID: 1308130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
    Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
    J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.
    Abraira C; Colwell J; Nuttall F; Sawin CT; Henderson W; Comstock JP; Emanuele NV; Levin SR; Pacold I; Lee HS
    Arch Intern Med; 1997 Jan; 157(2):181-8. PubMed ID: 9009975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial.
    Abraira C; McGuire DK
    Am Heart J; 1999 Nov; 138(5 Pt 1):S360-5. PubMed ID: 10539798
    [No Abstract]   [Full Text] [Related]  

  • 11. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Agrawal L; Emanuele NV; Abraira C; Henderson WG; Levin SR; Sawin CT; Silbert CK; Nuttall FQ; Comstock JP; Colwell JA
    Diabetes Care; 1998 Apr; 21(4):510-5. PubMed ID: 9571333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).
    Pitale SU; Abraira C; Emanuele NV; McCarren M; Henderson WG; Pacold I; Bushnell D; Colwell JA; Nuttall FQ; Levin SR; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Sep; 23(9):1316-20. PubMed ID: 10977025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
    Shichiri M; Kishikawa H; Ohkubo Y; Wake N
    Diabetes Care; 2000 Apr; 23 Suppl 2():B21-9. PubMed ID: 10860187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM.
    Henricsson M; Janzon L; Groop L
    Diabetes Care; 1995 Dec; 18(12):1571-6. PubMed ID: 8722053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators.
    Levin SR; Coburn JW; Abraira C; Henderson WG; Colwell JA; Emanuele NV; Nuttall FQ; Sawin CT; Comstock JP; Silbert CK
    Diabetes Care; 2000 Oct; 23(10):1478-85. PubMed ID: 11023140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
    Ohkubo Y; Kishikawa H; Araki E; Miyata T; Isami S; Motoyoshi S; Kojima Y; Furuyoshi N; Shichiri M
    Diabetes Res Clin Pract; 1995 May; 28(2):103-17. PubMed ID: 7587918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.